1Kouloulias EV, Kouvaris RJ ,Anpytas C,et al. An intra-patient doses-cation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases: monitoring using image-processing techniques. Strahlenther Onkol, 2003,179(7) :471-479.
2Theriauh RL, Lipon A, Hortodajyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized, placebo-controlled trial. Protrocol 18 Aredia Breast Cancer Study Group. J Oncol, 1999,17(3) :846-854.
3Splinter TA. Caehexia and cancer: a clinician's view. Ann Oncal, 1992,3(8) :525-527.
4Dunford JE,Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing BPs. J Pharmacol Exp Ther ,2001,296 (2) :235-242.
5Fleisch H. Pharmacodynamics of bisphosphonates. In: Fleisch H. Bisphosphonates in bone disease. Third edition. San Diego: Academic Press,2000.30- 60.
6Chesnut Ⅲ CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004,19 (8): 1241-1249.
7Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheuamatol, 2002,29(10) :2200-2208.
8Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003,42(6) :743-749.
9Koh LK. The diagnosis and management of hypercalcaemia. Ann Acad Med Singapore, 2003 ,32(1) :129-139.
10Fleisch H. Effects of bisphosphonates on bone resoption. In: Fleisch H. Bisphosphonates in bone diseases. Third edition . San Digego :Academic Press,2000. 34-38.
4Boissier S,Ferreras M,Peyruchaud O,et al.Bisphosphonates inhibit breast and prostate carcinoma cell invasion,an early in the formation of bone metastases[J].Cancer Res,2000,60(11):2949-2954.
5Magnetto S,Boissier S,Delmas PD,et al.Additive antitumor of taxoids in combination with the bisphosphonate ibandonate against invasion and adhesion of human breast carcinoma cells to bone[J].Int J Cancer,1999,83(2):263-269.
6Seegenschmiedt MH,Oppenkowski R.Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma[J].Schweiz Rundsch Med Prax,2001,90(38):1645-1652.
7Karagol H, Saip P, Uygun K, et al. Evaluation of prognostic fac- tors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Med Oncol, 2011,23(4) : 543 -548.
8Rao GG, Miller DS. Hormonal therapy in epithelial ovarian canc- er. Expert Rev Antieaneer Ther,2010, 6 ( 1 ) : 43 - 47.
9Melstrom LG, Melstrom KA Jr, Ding XZ, et al. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol, 2009, 22 (7) : 805 - 814.
10Palombine J. Cancer - related weight loss. Clin J Oncol Nuts, 2012,10(6) : 831 -832.
